Dawn Health raises fresh capital to transform clinical trials
Dawn Health, a Copenhagen-based digital health company, has secured €21.5 million in new funding to accelerate the digitisation of clinical trials and deepen patient engagement across the pharmaceutical industry. The round, backed by a mix of institutional investors and strategic healthcare partners, will fuel the company’s expansion in Europe and North America.
Building a digital backbone for drug development
Founded to tackle the inefficiencies that slow down traditional research, Dawn Health develops regulatory-grade digital health platforms that support every stage of a clinical trial, from patient recruitment and onboarding to remote monitoring and real‑world data collection.
Using secure mobile apps and connected devices, the company’s technology enables sponsors to run decentralised clinical trials, where patients can participate from home instead of travelling regularly to hospitals or research centres. This approach aims to shorten timelines, reduce costs, and make participation more inclusive for patients who live far from trial sites or have mobility challenges.
Patient engagement at the centre
A key differentiator for Dawn Health is its focus on sustained patient engagement. The platform offers personalised reminders, educational content, and two‑way communication tools that keep participants informed and motivated throughout a study. By improving adherence and reducing drop‑out rates, the company helps sponsors generate higher‑quality data and more reliable outcomes.
The new capital will be invested in enhancing the company’s AI‑driven analytics, expanding integrations with electronic health records, and strengthening compliance with strict regulatory frameworks such as GDPR and GxP guidelines.
Strategic push into global pharma partnerships
With this funding, Dawn Health plans to scale its collaborations with global pharmaceutical companies, contract research organisations and hospital systems. The company aims to position its platform as a core infrastructure layer for next‑generation drug development, supporting both early‑stage research and large, late‑phase studies.
As the life sciences sector increasingly embraces digital therapeutics, remote monitoring and data‑driven decision making, the latest investment underscores growing confidence that technology‑enabled trials will become a standard feature of how new medicines are brought to market.